Drug Patents owned by Ironshore Pharms

1. Drug name - JORNAY PM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
60MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.